No significant difference was observed between the groups, and furthermore, no difference was found in DAS28.51The second trial included 64 RA patients and focused on the effect of vitamin K1 on the biomarker of joint destruction (serum levels of matrix metalloproteinase-3 [MMP-3]). The gene discussed is MMP3; the disease is rheumatoid arthritis.